C. Hudis

Oncology · 2001–2018

A researcher in the Science corpus: 26 papers; trusts 1 researcher and is trusted by 8 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 161 citations into it; #287 of 1,698 by trust here, #159 by citations
• Molecular Biology — 67 citations into it
• Radiology, Nuclear Medicine and Imaging — 26 citations into it; #1,085 of 3,265 by trust here, #956 by citations

Whom C. Hudis trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Y. Yarden

Who trusts C. Hudis overall

1. N. Almansour
2. H. Horlings
3. N. Hynes
4. M. Wieduwilt
5. R. Roskoski
6. X. Zhang

Papers from C. Hudis's perspective

Ordered by how strongly the researchers C. Hudis trusts endorse each paper. Same corpus, a different order for every researcher.

1. Molecular portraits of human breast tumours (Nature)
2. Repeated observation of breast tumor subtypes in independent gene expression data sets (Proceedings of the National Academy of Sciences of the United States of America)
3. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications (Proceedings of the National Academy of Sciences of the United States of America)
4. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. (Journal of Clinical Oncology)
5. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma (Clinical Cancer Research)
6. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (Journal of the National Cancer Institute)
7. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (New England Journal of Medicine)
8. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. (New England Journal of Medicine)
9. A multigenic program mediating breast cancer metastasis to bone. (Cancer Cell)
10. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (New England Journal of Medicine)

Their papers

• Latent bone metastasis in breast cancer tied to Src-dependent survival signals (2009) — 677 citations
• ESR1 ligand binding domain mutations in hormone-resistant breast cancer (2013) — 1,143 citations
• American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. (2015) — 818 citations
• The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers (2018) — 851 citations
• Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment (2017) — 1,960 citations
• MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer (2017) — 605 citations
• 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (2017) — 674 citations
• Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. (2016) — 784 citations
• Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. (2016) — 2,083 citations
• Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). (2015) — 867 citations
• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014) — 634 citations
• Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. (2014) — 736 citations
• Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. (2013) — 1,167 citations
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) — 3,678 citations
• Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer (2013) — 630 citations
• Triple-negative breast cancer: an unmet medical need. (2011) — 790 citations
• Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in a Randomized Trial of Chemotherapy for Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer (2009) — 1,334 citations
• Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. (2007) — 789 citations
• Trastuzumab--mechanism of action and use in clinical practice. (2007) — 2,521 citations
• The global breast cancer burden: variations in epidemiology and survival. (2005) — 610 citations